

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
1/1/10	ADMINISTRATIVE PA	REQUIRED TO DETERMINE B VERSUS D COVERAGE	LIFETIME	REQUIRES DOCUMENTATION OF DIAGNOSIS AND APPLICABLE MEDICATION HISTORY FOR DETERMINATION OF PART D COVERAGE.	NON COVERED PART D DRUGS
1/10/10	AFINITOR	CRITERIA PENDING CMS APPROVAL			
1/10/10	BRANDED PPIS	CRITERIA PENDING CMS APPROVAL			
1/1/10	BRANDED SEDATIVE HYPNOTICS	CRITERIA PENDING CMS APPROVAL			
1/1/10	CYMBALTA	CRITERIA PENDING CMS APPROVAL			
1/1/10	ERYTHROPOESIS STIMULATING AGENTS	COVERED FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC RENAL FAILURE, INCLUDING PATIENTS ON DIALYSIS (END-	THREE MONTHS	DOCUMENTATION OF DIAGNOSIS, LABORATORY VALUES OF HEMOGLOBIN AND HEMATOCRIT, AND MEDICATION HISTORY, WHERE APPLICABLE. A	ANEMIA DUE TO FOLATE, VITAMIN B12, IRON DEFICIENCIES, HEMOLYSIS, BLEEDING, OR BONE MARROW FIBROSIS. ANEMIA ASSOCIATED WITH

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>STAGE RENAL DISEASE) AND PATIENTS NOT ON DIALYSIS, TO ELEVATE OR MAINTAIN THE RBC LEVEL (AS MANIFESTED BY HEMATOCRIT OR HEMOGLOBIN DETERMINATIONS) AND TO DECREASE THE NEED FOR TRANSFUSIONS IN THESE PATIENTS. ALSO COVERED FOR ANEMIA SECONDARY TO ACTIVE CHEMOTHERAPY OF SOLID TUMORS, ANEMIA SECONDARY TO ACTIVE ZIDOVUDINE (AZT) THERAPY, ANEMIA IN MYELODYSPLASTIC DISORDERS, AND PROPHYLACTIC USE DURING MAJOR SURGERIES. ARANESP AND EPOGEN USE REQUIRES TRIAL AND FAILURE OF PROCRT.</p>		<p>HEMOGLOBIN LEVEL OF LESS THAN 10 MG/DL IS REQUIRED FOR INITIAL THERAPY. DOSAGE ADJUSTMENTS ARE REQUIRED TO MAINTAIN HEMOGLOBIN BETWEEN 10 MG/DL AND 12 MG/DL, WITH DISCONTINUATION IF HEMOGLOBIN EXCEEDS 12 MG/DL.</p>	<p>TREATMENT OF ACUTE AND CHRONIC MYELOGENOUS LEUKEMIAS OR ERYTHROID CANCERS. ANEMIA DUE TO CANCER TREATMENT IN PATIENTS WITH UNCONTROLLED HYPERTENSION. ANEMIA NOT ASSOCIATED WITH CANCER TREATMENT OR RENAL DISEASE UNDER INCLUSIONS. ANEMIA ASSOCIATED ONLY WITH RADIOTHERAPY. PROPHYLACTIC USE TO PREVENT CHEMOTHERAPY INDUCED ANEMIA. PROPHYLACTIC USE TO REDUCE TUMOR HYPOXIA. ERYTHROPOIETIN-TYPE RESISTANCE DURE TO NEUTRALIZING ANTIBODIES.</p>

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
1/1/10	GASTROINTESTINAL AGENTS	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D. COVERED FOR WOMEN 18 YEARS OR OLDER AND DIAGNOSED WITH IBS WITH CONSTIPATION. COVERED FOR ADULTS WITH FOR THE TREATMENT OF CHRONIC IDIOPATHIC CONSTIPATION. DOCUMENTATION OF FAILURE WITHIN THE LAST 12 MONTHS OF USE OF A FIBER LAXATIVE AND ONE OF THE FOLLOWING: A STIMULANT LAXATIVE OR AN OSMOTIC LAXATIVE. DRUG INDUCED CONSTIPATION MUST BE RULED OUT.	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE YEAR		
1/1/10	GROWTH HORMONE	COVERED FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE	INITIAL APPROVAL FOR ONE YEAR AND RENEWAL CAN BE OBTAINED IF DOCUMENTED CLINICAL RESPONSE	NOT COVERED FOR EDEMA, ARTHRALGIAS, OR CARPAL TUNNEL SYNDROME.

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>DEFICIENCY OF CHILDHOOD ONSET OR ADULT ONSET, COVERED IF INITIAL DIAGNOSIS BASED ON TWO GROWTH HORMONE STIMULATION TESTS AND THAT THE PATIENT DOES NOT HAVE EDEMA, ARTHRALGIAS, OR CARPAL TUNNEL SYNDROME. GROWTH HORMONE IS COVERED FOR ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. SEROSTIM IS COVERED FOR AIDS WASTING CACHEXIA. NORDITROPIN IS COVERED FOR NOONAN SYNDROME, TURNER SYNDROME, AND ADULT GROWTH HORMONE DEFICIENCY. NUTROPIN IS COVERED FOR TURNER SYNDROME,</p>	YEAR	WITH THAT THERAPY.	

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>AND ADULT GROWTH HORMONE DEFICIENCY. OMNITROPE AND SAIZEN ARE COVERED FOR ADULT GROWTH HORMONE DEFICIENCY. ZORBTIVE IS COVERED FOR THE TREATMENT OF SHORT-BOWEL SYNDROME IN PATIENTS RECEIVING SPECIALIZED NUTRITIONAL SUPPORT.SOMAVERT IS COVERED FOR ACROMEGALY. INITIAL APPROVAL FOR 1 YEAR AND RENEWAL CAN BE OBTAINED IF CLINICAL RESPONSE WITH THERAPY.</p>			
1/1/10	HEPATITIS C TREATMENT	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D. COVERED FOR HEPATITIS C VIRUS INFECTION. COVERED WHEN APPROPRIATE	INITIATION OF THERAPY - 12 WEEKS APPROVAL, CONTINUATION THERAPY -	DOCUMENTATION OF APPROPRIATE CONCOMITANT RIBAVARIN DOSAGE MAY BE REQUIRED. CLINICAL DOCUMENTATION OF RESPONSE TO	

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		DOSES OF CONCOMITANT RIBAVARIN ARE UTILIZED FOR THE APPROPRIATE VIRAL GENOTYPE. INITIAL THERAPY WILL BE APPROVED FOR 12 WEEKS	24 TO 48 WEEKS APPROVAL	THERAPY MAY BE REQUIRED FOR REQUESTS FOR CONTINUATION OF THERAPY. DOCUMENTATION OF VIRAL GENOTYPE MAY BE REQUIRED.	
1/1/10	HIGH RISK MEDICATIONS IN ELDERLY	COVERED FOR PATIENTS 65 YEARS OR OLDER FOR ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D IF INTOLERANCE, CONTRAINDICATIONS, OR TRIAL WITH FAILURE HAS OCCURRED WITH SAFER ALTERNATIVES, OR IF DOCUMENTATION OF SHORT TERM USE ONLY. PROPOXYPHENE AND PENTAZOCINE ARE COVERED IF PATIENT IS INTOLERANT TO OR HAS FAILED OTHER	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE YEAR		

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>AGENTS FOR MODERATE PAIN SUCH AS ACETAMINOPHEN OR ASPIRIN WITH OR WITHOUT CODEINE OR HYDROCODONE. CHLORPROPAMIDE IS COVERED IF PATIENT HAS FAILED OR IS INTOLERANT TO SAFER ALTERNATIVES SUCH AS GLYBURIDE, GLIPIZIDE, PRECOSE, PRANDIN, OR THIAZOLIDINEDIONES. MEPERIDINE IS COVERED IF PATIENT IS INTOLERANT TO SAFER NARCOTIC ALTERNATIVES SUCH AS MORPHINE OR OXYCODONE. MEPROBAMATE IS COVERED IF PATIENT IS INTOLERANT TO OR HAS FAILED OTHER ANXIOLYTIC AGENTS SUCH AS BUSPIRONE. INDOMETHACIN IS APPROVED IF PATIENT IS</p>			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>INTOLERANT TO OR HAS FAILED THERAPY WITH OTHER SAFER NONSTEROIDAL ALTERNATIVES SUCH AS MELOXICAM OR CELECOXIB. DIPHENHYDRAMINE IS APPROVED IF PATIENT HAS FAILED OR IS INTOLERANT TO OTHER SAFER ALTERNATIVE SEDATIVE OR ANXIOLYTIC AGENTS SUCH AS ZOLPIDEM. FLUOXETINE IS COVERED FOR PATIENTS WHO HAVE A HISTORY OF USE. FOR THOSE PATIENTS INITIATING THERAPY, FLUOXETINE IS COVERED IF PATIENT HAS FAILURE OF OR INTOLERANCE TO SAFER ALTERNATIVE SSRI AGENTS SUCH AS CITALOPRAM, ESCITALOPRAM OR PAROXETINE.</p>			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
1/1/10	HP ACTHAR GEL	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D. ACTH GEL MAY BE CONSIDERED MEDICALLY NECESSARY FOR USE IN DIAGNOSTIC TESTING OF ADRENOCORTICAL FUNCTION, HOWEVER, COSYNTROPIN SHOULD BE USED FOR THIS TEST IN MOST CASES. REPOSITORY CORTIC	COVERED FOR REQUESTED DURATION UP TO THREE MONTHS		
1/1/10	INJECTABLE DIABETIC AGENTS	BYETTA IS COVERED FOR PATIENTS WHO HAVE TYPE 2 DIABETES WITH CONCURRENTLY PRESCRIBED METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, A COMBINATION OF METFORMIN AND A SULFONYLUREA OR A COMBINATION OF METFORMIN AND A	LIFETIME	REQUIRES DOCUMENTATION OF DIAGNOSIS AND MEDICATION HISTORY OR INTOLERANCE(S).	NON TYPE 2 DIABETES DIAGNOSIS. NO EVIDENCE OF CONCURRENT METFORMIN OR SULFONYLUREA USE. BYETTA WILL NOT BE COVERED FOR WEIGHT LOSS IN PATIENTS WITH OR WITHOUT DIABETES.

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>THIAZOLIDINEDIONE (A TRIAL OF AT LEAST TWO OF THESE THREE AGENTS IS REQUIRED) AND HAVE DEMONSTRATED A LACK OF EFFICACY OF INSULIN AND DOCUMENTATION THAT INSULIN WILL BE DISCONTINUED. IN ADDITION TO THE ABOVE CRITERIA THE PATIENT MUST HAVE A HEMOGLOBIN A1C OF GREATER THAN 7 PER CENT. SYMLIN IS COVERED FOR PATIENTS THAT HAVE FAILED INTENSIVE TREATMENT WITH INSULIN MONOTHERAPY. SYMLIN IS COVERED FOR CONCURRENT USE WITH AN INSULIN PRODUCT. COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE COVERED BY PART D.</p>			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
1/1/10	MOZOBIL	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D. COVERED FOR PATIENTS REQUIRING AUTOLOGOUS TRANSPLANTATION, WHEN POOR RESPONSE IS DOCUMENTED TO APHERESIS WITH GRANULOCYTE COLONY STIMULATING FACTOR ALONE, AND COVERED FOR PATIENTS WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA.	COVERED FOR DURATION REQUESTED UP TO ONE MONTH.	DOCUMENTATION OF DIAGNOSIS AND THAT GRANULOCYTE COLONY STIMULATING FACTOR IS ADMINISTERED CONCOMITANTLY, AND DOCUMENTATION OF POOR RESPONSE TO APHERESIS WITH GRANULOCYTE COLONY STIMULATING FACTOR ALONE.	
1/1/10	NARCOTIC ANALGESICS	ACTIQ AND FENTORA ARE COVERED FOR CANCER OR CANCER RELATED DIAGNOSIS IN PATIENTS ALREADY RECEIVING LONG ACTING OPIOIDS. OXYCONTIN EXTENDED RELEASE TABLETS ARE COVERED FOR THE	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE YEAR	REQUIRES DOCUMENTATION OF DIAGNOSIS AND MEDICATION HISTORY OR INTOLERANCE(S).	

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME, AND TRIALS OF EXTENDED RELEASE MORPHINE, METHADONE, AND FENTANYL PATCHES IS UNSUCCESSFUL. COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D.</p>			
1/1/10	NEUROPATHIC PAIN TREATMENT	CRITERIA PENDING CMS APPROVAL			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
1/1/10	OMEPRAZOLE 40MG	CRITERIA PENDING CMS APPROVAL			
1/1/10	PROMACTA	CRITERIA PENDING CMS APPROVAL			
1/1/10	PULMONARY AGENTS	LETAIRIS, REVATIO, ADCIRCA, TRACLEER	ONE YEAR OR		COVERAGE FOR REVATIO IS NOT PROVIDED IN

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		AND VENTAVIS ARE COVERED FOR ALL FDA APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.	COVERED THROUGH REMAINDER OF PLAN YEAR WHICHEVER IS GREATER		SITUATIONS WHERE PATIENTS ARE RECEIVING NITRATE THERAPY.
1/1/10	RELISTOR	CRITERIA PENDING CMS APPROVAL			
1/1/10	REMICADE	COVERED FOR MEMBERS WITH MODERATE TO SEVERELY ACTIVE CROHN'S WHO HAVE AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY. CONVENTIONAL THERAPY INCLUDES, BUT IS NOT LIMITED TO: SULFASALAZINE, MESALAMINE OR 5-ASA AGENTS, CORTICOSTEROIDS, ANTIBIOTICS, OR OTHER DRUGS THAT AFFECT THE IMMUNE SYSTEM SUCH AS AZATHIOPRINE OR 6-	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE YEAR	REQUIRES DOCUMENTATION OF DIAGNOSIS, MEDICATION HISTORY AND/OR INTOLERANCE(S).	REMICADE IS NOT COVERED AS FIRST LINE TREATMENT OF RHEUMATOID ARTHRITIS OR CROHN'S DISEASE (OTHER THAN FISTULIZING CROHN'S DISEASE, SEE INCLUSION CRITERIA), THEREFORE REMICADE IS NOT COVERED WHEN CONVENTIONAL, CONSERVATIVE TREATMENTS HAVE NOT BEEN ATTEMPTED FOR THESE DIAGNOSES. REMICADE IS NOT COVERED FOR DERMATOLOGIC MANIFESTATIONS OF PSORIASIS. REMICADE IS NOT COVERED FOR

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>MERCAPTOPURINE (6-MP). REMICADE IS ALSO COVERED FOR FIRST-LINE TREATMENT FOR MEMBERS WITH CROHN'S DISEASE ASSOCIATED WITH FISTULAS TO REDUCE THE NUMBER OF DRAINING ENTEROCUTANEOUS FISTULA(S). COVERED FOR THE TREATMENT OF MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS FOR THE REDUCTION OF THE SIGNS AND SYMPTOMS ASSOCIATED WITH THE DISEASE FOR MEMBERS WHO HAVE AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY. CONVENTIONAL THERAPY INCLUDES BUT IS NOT LIMITED TO: NSAIDS (NON-</p>			<p>JUVENILE RHUMATOID ARTHRITIS. REMICADE IS NOT COVERED FOR OTHER SPONDYLOARTHROPATHIES EXCEPT FOR ANKLYOSING SPONDYLITIS AND PSORIATIC ARTHRITIS. REMICADE IS NOT COVERED IN PATIENTS WITH ACTIVE SERIOUS INFECTIONS.</p>

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>STEROIDAL ANTI-INFLAMMATORY DRUGS), COX-2 INHIBITORS, CORTICOSTEROIDS, METHOTREXATE, OR GOLD INJECTIONS. REMICADE IS COVERED FOR ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS, BEHCET'S DISEASE. REMICADE IS COVERED FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY. COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D.</p>			
1/1/10	SANCUSO	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE	COVERED THROUGH REMAIN-	COVERED IF TREATMENT WITH GENERIC	SANCUSO IS NOT COVERED FOR HYPEREMESIS

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		EXCLUDED BY PART D. COVERED FOR THE PREVENTION AND OR TREATMENT OF NAUSEA AND OR VOMITING ASSOCIATED WITH CHEMOTHERAPY AND OR RADIATION.	DER OF PLAN YEAR UP TO ONE YEAR	ONDANSETRON AND ORAL GRANISETRON IS NOT EFFECTIVE OR IS NOT TOLERATED.	GRAVIDARUM, NAUSEA AND VOMITING OF PREGNANCY, AND POST-OPERATIVE NAUSEA AND VOMITING.
1/1/10	SAPROPTERIN HYDROCHLORIDE	COVERED FOR PATIENTS WITH HYPERPHENYLALANINEMIA (HPA) DUE TO TETRAHYDROBIOPTERIN (BH4) RESPONSIVE PHENYLKETONURIA (PKU).	TWO MONTHS AUTHORIZATION WILL BE EXTENDED FOR ONE YEAR IF DOCUMENTED RESPONSE AFTER INITIAL THERAPY OF 2 MONTHS. DOCUMENTED RESPONSE INCLUDES A 30% OR GREATER REDUC-	DOCUMENTATION OF DIETARY RESTRICTIONS AND DIAGNOSIS FOR APPROVAL.	EXCLUDED FOR NON FDA OR UNSUPPORTED USE.

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
			TION IN PHENYLALANINE FROM BASELINE.		
1/1/10	TEKTURN/HCT	CRITERIA PENDING CMS APPROVAL			
1/1/10	TNF ALPHA AGENTS	FOLLOWING CRITERIA ARE USED IN REVIEWING ENBREL: 1. FOR RHEUMATOID ARTHRITIS, JUVENILE RA OR PSORIATIC ARTHRITIS, ENBREL REQUIRES A THREE MONTH TRIAL ON TWO CONCURRENT NONBIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), ONE OF WHICH MUST BE METHOTREXATE UNLESS CONTRAINDICATED. 2. FOR MODERATE TO SEVERE PSORIASIS, A MINIMUM OF 3 MONTHS OF PREVIOUS	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE YEAR	COVERAGE MAY ALSO REQUIRE DOCUMENTATION OF EVALUATION FOR INFECTION RISKS, ESPECIALLY TUBERCULOSIS.	TNF ALPHA AGENTS ARE NOT COVERED IN PATIENTS WITH ACTIVE SERIOUS INFECTIONS. REQUIRES DOCUMENTATION OF DIAGNOSIS AND MEDICATION HISTORY OR INTOLERANCE(S).

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>TREATMENT WITH A TOPICAL STEROID AND 3 MONTHS TREATMENT WITH PUVA (UNLESS PUVA CONTRAINDICATED) AND THERAPY MUST BE SUPERVISED BY A DERMATOLOGIST. 3. FOR ALKYLOSING SPONDYLITIS, REQUIRES THERAPY IS BEING SUPERVISED BY A RHEUMATOLOGIST. FOLLOWING CRITERIA ARE USED IN REVIEWING HUMIRA:</p> <p>1. FOR RHEUMATOID ARTHRITIS, JUVENILE RA OR PSORIATIC ARTHRITIS, HUMIRA REQUIRES A THREE MONTH TRIAL ON TWO CONCURRENT NONBIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), ONE OF WHICH MUST BE METHOTREXATE UNLESS CONTRAINDICATED.</p>			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>2. FOR CROHN'S DISEASE, HUMIRA IS COVERED FOR PATIENTS AGE 18 YEARS OR OLDER, WITH A DIAGNOSIS OF MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WITH A HISTORY OF INADEQUATE RESPONSE TO CONVENTIONAL THERAPY. 3. FOR ALKYLOSING SPONDYLITIS, REQUIRES THERAPY IS BEING SUPERVISED BY A RHEUMATOLOGIST. 4. FOR MODERATE TO SEVERE PSORIASIS, A MINIMUM OF 3 MONTHS OF PREVIOUS TREATMENT WITH A TOPICAL STEROID AND 3 MONTHS TREATMENT WITH PUVA (UNLESS PUVA CONTRAINDICATED) AND THERAPY MUST BE SUPERVISED BY A</p>			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>DERMATOLOGIST. FOLLOWING CRITERIA ARE USED IN REVIEWING KINERET:            1. FOR RHEUMATOID ARTHRITIS, KINERET REQUIRES A THREE MONTH TRIAL ON TWO CONCURRENT DISEASE NONBIOLOGIC MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), ONE OF WHICH MUST BE METHOTREXATE UNLESS CONTRAINDICATED AND TREATMENT FAILURE OR CONTRAINDICATION TO ENBREL AND HUMIRA. AS NEW FDA APPROVED INDICATIONS BECOME AVAILABLE PLAN WILL CONSIDER COVERAGE ACCORDINGLY. COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART</p>			

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		D.			
1/1/10	WOUND CARE	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE EXCLUDED BY PART D. COVERED FOR PATIENTS WITH CHRONIC NEUROPATHIC DIABETIC ULCER OF THE LOWER EXTREMITY.	COVERED THROUGH REMAINDER OF PLAN YEAR UP TO ONE YEAR	REQUIRES ADEQUATE TISSUE OXYGENATION AT THE SITE OF THE NEUROPATHIC DIABETIC ULCER, AND THAT THERE IS A FULL THICKNESS ULCER (FOR EXAMPLE STAGE THREE OR FOUR) EXTENDING THROUGH THE DERMIS INTO SUBCUTANEOUS TISSUE. IN ADDITION, REQUIRES THAT THE PATIENT IS PARTICIPATING IN A COMPREHENSIVE WOUND CARE TREATMENT PLAN INCLUDING SUCH MODALITIES AS DEBRIDEMENT, PRESSURE RELIEF (FOR EXAMPLE, NON WEIGHT BEARING) AND INFECTION CONTROL.	
1/1/10	XENAZINE	COVERED FOR ALL FDA APPROVED USES NOT OTHERWISE	LIFETIME		COVERAGE FOR XENAZINE WILL NOT BE PROVIDED FOR PATIENTS WHO HAVE

**2010 Prior Authorization Information and Criteria  
BCN Advantage**

Effective Date	Drugs/Categories of Drugs	Coverage Criteria	Coverage Duration	Other Information	Non-Covered Uses
		<p>EXCLUDED BY PART D. COVERED FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE. FOR DOSES ABOVE 50MG PER DAY, DOCUMENTATION OF CYP2D6 GENOTYPE OF THE PATIENT WILL BE REQUIRED.</p>			<p>HEPATIC FUNCTION IMPAIRMENT, PATIENTS WHO ARE ACTIVELY SUICIDAL OR WHO HAVE UNTREATED OR INADEQUATELY TREATED DEPRESSION, OR PATIENTS TAKING MONAMINE OXIDASE INHIBITORS OR RESERPINE.</p>